The necrotic lesion possibly had a hepatocellular carcinoma component, and the liver cancer before Atezo/Bev treatment was possibly a combined hepatocellular-cholangiocarcinoma or cholangiolocellular carcinoma. The patient died of parkinsonism 1 year after surgery, without recurrence of liver cancer.

After irradiation to the pain area, paclitaxel and bevacizumab therapy was administered, and a marked reduction of pulmonary and liver metastases, and the disappearance of pain were observed. Local hepatic therapy with TAE followed by chemotherapy was thought to have helped the patient overcome the rapid tumor growth.

Postoperatively, tamoxifen, a CDK4/6 inhibitor, and radiotherapy were administered...Despite initiating weekly paclitaxel plus bevacizumab, the disease progressed rapidly, and she died 4 months later. Notably, OMS symptoms did not recur. This case highlights paraneoplastic OMS as an initial manifestation of breast cancer, with neurological improvement following systemic therapy.

P2, N=48, Not yet recruiting, Fudan University

P=N/A, N=170, Recruiting, Centre Hospitalier Universitaire, Amiens | Unknown status --> Recruiting | Trial completion date: Jan 2021 --> Jan 2027 | Trial primary completion date: Jan 2021 --> Jan 2027

P2, N=153, Recruiting, RTOG Foundation, Inc. | Not yet recruiting --> Recruiting

P2, N=30, Recruiting, First Affiliated Hospital of Wenzhou Medical University

cGAS functions as a dual biomarker, predicting poor prognosis after hepatectomy but favorable response to immunotherapy. These findings underscore the clinical relevance of cGAS and its potential to guide personalized HCC treatment.

Primary and secondary pseudo-stability/progression occur in a non-trivial proportion of patients across cancer types. Outcomes after pseudo-stability/progression are dependent on cancer type and initial response. Uncovering the clinical and molecular features of pseudo-stability/progression subtypes may guide treatment decisions and identify patients who may benefit from continued immunotherapy despite radiographic progression.

Compared with atezolizumab monotherapy, a combination of chemotherapy, atezolizumab, and bevacizumab led to dramatically improved progression-free survival in patients with mismatch repair-deficient /microsatellite instability-high metastatic colorectal cancer. Because these patients often experience disease progression on immunotherapy, the results suggest that the combination approach could improve how they fare.

Tumor-intrinsic activation of the NRF2-COX2-PGE₂ axis drives immune cold TMEs and mediates Atez/Bev resistance in HCC. Targeting this pathway may enhance efficacy, and plasma PGE₂ represents a non-invasive biomarker for stratification.

These results demonstrate OS advantage for maintenance treatment of adult females with newly diagnosed, advanced stage IIIb-IV ovarian cancer with HRP status and cTMB-H profile who are in complete response after debulking surgery and frontline platinum-based doublet chemotherapy.